Processa Pharmaceuticals Inc(PCSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.59 | Insider Own | 15.46% | Shs Outstand | 2.8M | Perf Week | - |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | 23% | Shs Float | 2.4M | Perf Month | -12.8% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 14.91% | Short Float | 0.64% | Perf Quarter | -5.15% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 10.63% | Short Ratio | 0.07 | Perf Half Y | -24.28% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -262.17% | Short Interest | 0.01M | Perf YTD | -36.11% |
| Book/sh | -0.11 | P/C | 25.7 | EPS past 3/5Y | 77% 61.77% | ROE | -464.2% | 52W High | -86.86% ($14.00) | Perf Year | -65.45% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 10.17% ($1.67) | Perf 3Y | -98.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 90.37% | Gross Margin | - | Volatility(W/M) | 6.74% 6.63% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 0.87 | EPS Q/Q | 81.21% | Profit Margin | - | RSI (14) | 41.91 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.87 | Sales Q/Q | - | SMA20 | -5.83% ($1.95) | Beta | 1.19 | Target Price | $25 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -15.36% ($2.17) | Rel Volume | 0.04 | Prev Close | $1.84 |
| Employees | 12 | LT Debt/Eq | - | EPS/Sales Surpr. | -13.64% - | SMA200 | -30.06% ($2.63) | Avg Volume(3M) | 0.23M | Price | $1.84 |
| IPO | 2013/11/21 | Option/Short | No/Yes | Trades | 127 | Volume | 9,402 | Change | - |
🧬 Processa Pharmaceuticals () is a clinical-stage biopharma specializing in developing 'Next Generation Cancer (NGC)' therapies by modifying the metabolism and distribution of already FDA-approved anticancer drugs to improve safety and efficacy. Its lead asset, PCS6422 (NGC-Cap), is in Phase 2 for metastatic breast cancer, while irinotecan-based PCS11T (NGC-Iri) is in preclinical development, reflecting the company's strategy of "upgrading" existing classes of anticancer drugs.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual That is 4% of its average volume.
PCSA has weak earning power
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #550 of 592 in the industry
Based on market cap of $5M.
CDIO#547 Cardio Diagnostics Holdings Inc $6M PER - 
NCNA#548 NuCana plc ADR $6M PER - 
XBIO#549 Xenetic Biosciences Inc $5M PER - PCSA#550 Processa Pharmaceuticals Inc $5M PER - 
ONCO#551 Onconetix Inc $5M PER - 
FAQ
What kind of company is PCSA?
PCSA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PCSA?
The market cap of PCSA is approximately $5M, ranking 5,681 within its sector.
What is the 52-week high and low for PCSA?
PCSA has recorded a 52-week high of $14.00 and a low of $1.67.
